TP53 mutations and survival in squamous-cell carcinoma of the head and neck.

By M. Poeta, J. Manola, M. Goldwasser, A. Forastiere, N. Benoit, J. Califano, J. Ridge, J. Goodwin, D. Kenady, John K. Saunders and 3 more. New England Journal of Medicine, 2007

780 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Otorhinolaryngology

View Paper: https://www.semanticscholar.org/paper/46d6f518ed83871a93179a2ddad61c3f357e92ea

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Varda Rotter
2. M. Hallek
3. Ruud H. Brakenhoff
4. R. Brosh

In Oncology

1. Varda Rotter
2. M. Hallek
3. Ruud H. Brakenhoff
4. R. Brosh
5. C. R. Leemans
6. B. Braakhuis

Citations in the corpus

• The molecular biology of head and neck cancer (2011, background): “HPV-positive tumours are typically TP53 wild type and it has been shown that the presence and type of TP53 mutation is also of prognostic relevanc”
• When mutants gain new powers: news from the mutant p53 field (2009, background): “In addition, some studies could demonstrate better prognostic values when their data were stratified not only according to the mere presence of TP53 mutations, but also according to the predicted or experimentally measured effect of these mutations on p53 structure or functio”
• TP53 mutation and survival in chronic lymphocytic leukemia. (2010, background): “TP53 mutations have been associated with poor prognosis in a number of cancers (eg, breast cancer, head and neck cancer, highgrade lymphoma).(31,32) The clinical effect of TP53 mutations seems to be particularly profound in CLL, which may partly be explained by the relatively benign course of patien”